Evidence map›Paper›PMID 39621395›Full record

ReviewExperimental and clinical psychopharmacology2025

A comprehensive review on oral nicotine pouches: Available scientific evidence and future research needs.

C Austin Zamarripa, Ashley N Dowd, Harrison J Elder, Lauren Czaplicki, Dana Tfayli, Kriti Rastogi, Johannes Thrul, Justin C Strickland, Meghan B Moran, Tory R Spindle

Abstract readReview
In one paragraph

Review in Experimental and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Nicotine Pouch Use Among U.S. Adults in 2023 and 2024.American journal of preventive medicine · 2026
    Article
  6. Article
  7. Article
  8. Oral nicotine pouches have arrived at U.S. college campuses.Journal of American college health : J of ACH · 2026
    Article
  9. Article
  10. Nicotine pouches: A wolf in sheep's clothing.Tobacco prevention & cessation · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

C Austin ZamarripaDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.
Ashley N DowdDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.
Harrison J ElderDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.
Lauren CzaplickiDepartment of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health.
Dana TfayliDepartment of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health.ORCID 0009-0004-0128-1884
Kriti RastogiDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.
Johannes ThrulDepartment of Mental Health, Johns Hopkins Bloomberg School of Public Health.
Justin C StricklandDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.
Meghan B MoranDepartment of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health.
Tory R SpindleDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.ORCID 0000-0002-2859-116X

Funding

HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSET32DA007209 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Eric C. Strain, Elise M Weerts · 1985 to 2026
$12.9M
Novel "Tobacco-Free" Oral Nicotine Pouches: The impact of Product Features and Marketing Influences on Abuse Liability, Perceptions, and Use Behavior in Smokers and Non-Nicotine UsersR01DA055962 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Meghan Bridgid Moran, Tory Richard Spindle · 2022 to 2026
$3.9M
National Institute on Drug Abuse/Food and Drug Administration Center for Tobacco ProductsNIDA NIH HHS R01 DA055962NIDA NIH HHS T32 DA007209
6 · The paper itself

Abstract

Oral nicotine pouches (ONPs) are an emergent class of tobacco products that, unlike conventional oral smokeless tobacco products, contain a nicotine powder instead of tobacco leaves. This review synthesizes available data on ONPs in key research domains including survey studies, marketing/advertising studies, chemical characterization and in vitro studies, and clinical studies. Research findings relevant for ONP regulations are summarized, including who uses these products and why, how marketing tactics influence appeal and use intentions, what harmful and potentially harmful constituents they contain, and what acute effects they have on humans. Taken together, the current data suggest that ONPs likely produce less harm to individual users than conventional tobacco products (e.g., moist snuff, cigarettes) and can acutely suppress nicotine/tobacco withdrawal symptoms among current cigarette smokers. Thus, ONPs may be a viable harm reduction option for individuals who switch completely to using them from conventional products. However, randomized controlled trials are needed to determine if established tobacco users would use ONPs long term, and more independent academic research is needed given that most ONP studies to date are tobacco industry-funded. Additionally, ONPs have qualities (e.g., flavors, marketing claims of "tobacco free") that could increase appeal among youth and young adults, and these products can deliver nicotine at levels sufficient to cause dependence; widespread adoption of ONPs among otherwise nicotine-naive individuals may reduce their net public health benefit. This review concludes by suggesting future research directions necessary to increase scientific understanding of ONPs and inform regulations for these increasingly popular products. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

Indexed as

NicotineSmoking CessationTobacco ProductsAdministration, OralHumansTobacco, SmokelessNicotine

Identifiers

PMID39621395
PMCPMC11959675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.